source
- Option-to-acquire deals remain rare in biotech's buzzy M&A seasonTwo recent deals are focusing attention on a relatively rare structure for biotech buyouts: the option-to-acquire. Drug developers are on pace to have one of the best dealmaking years in industry h…Endpoints · 30m ago↗ source
- Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanismRoche has taken its obesity strategy into uncharted territory via a $190 million upfront payment for a clinical-stage urocortin-2 analog from South Korea’s Hanmi Pharm.Fierce Biotech · 6h ago↗ source
- Merck and Moderna report positive topline results for personalized cancer vaccineA third death was reported in China’s expedited clinical trials, raising safety concerns for fast‑track studies in the region. Merck and Moderna announced positive topline data from their personal…